Aurobindo Pharma’s wholly owned subsidiary company -- Eugia Pharma Specialties has entered voluntary sub-licensing agreement with Medicines Patent Pool (MPP), to develop and market Nilotinib Capsules, originally developed by Novartis, for the treatment of chronic myeloid leukemia (CML) in 44 Low and Middle-Income Countries (LMIC), including the seven countries where patents on the product are pending or in force.
The product will be produced at the Eugia Pharma Specialities Unit-I, Medchal, Malkajgiri District, Telangana, India. The company has adequate capacities of world class standards, to meet the global demand for the product across the licensed territory.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
